| 样本编号 | SAMC4951952 |
|---|---|
| 外部数据库编号 | GSA-Human: HRS1618356 |
| 样品名称 | P60_FFPE |
| 样本标题 | P60_FFPE_tumor |
| 样品类型 | Human sample |
| 物种名称 | Homo sapiens |
| 描述信息 | tumor from patient P60 |
| 样本属性 | *该样本包含更多受控访问信息，请通过GSA-Human系统申请项目HRA010674数据获取。 |
| 发布日期 | 2025-12-01 |
| 项目编号 | PRJCA036922 |
| 提交者 | Lidi Xu (fei.zhou@tongji.edu.cn) |
| 提交单位 | Genecast Biotechnology |
| 提交日期 | 2025-04-07 |
| 资源名称 | 描述 |
|---|---|
| GSA-Human (1) | - |
| HRA010674 (Controlled Access) | The EVIDENCE was a phase 3, multicenter, randomized, open-label trial conducted in China (NCT02448797). This post-hoc minimal residual disease (MRD) analysis of the EVIDENCE study aimed to evaluate the prognostic and monitoring utility of ctDNA-based MRD in early-stage, resected EGFR-mutated NSCLC patients receiving adjuvant therapy. |